AUR-1001 is a first in class pathogenic-tailored drug for the prevention of thrombosis and fetal loss in patients with anti-phospholipid syndrome. There is an unmet medical need for new treatment in this condition.
The proposed drug is a human monoclonal antibody AUR-1001 directed against beta-2GPI. AUR-1001 competes with the patients “pathogenetic” autoantibodies that trigger the thrombotic events starting the complement cascade. AUR-1001 has higher affinity than patient autoantibodies, displaces them from the target and prevents the complement activation and the thrombogenic response.
The invention of AUR-1001 and its efficacy in animal models of human APS is described in a paper published in Blood. AUR-1001 human monoclonal antibody and its activity are covered in a patent application with a 2013 priority date.